IIA Programs

Finding Early Funding Through IIA Incentive Programs

The State of Israel is a world renowned source of innovation, with a unique supportive ecosystem for entrepreneurship and technology, and has an international reputation in the fields of high-tech industry, entrepreneurship and technological innovation.

The Israel Innovation Authority (IIA), formerly known as the Office of the Chief Scientist of the Ministry of Economy (& MATIMOP), which is responsible for the country’s innovation policy, is an independent and impartial public entity that operates for the benefit of the Israeli innovation ecosystem and Israeli economy as a whole. Its role is to nurture and develop Israeli innovation resources, while creating and strengthening the infrastructure and framework needed to support the entire knowledge industry.

Mor Research Applications helps and supports our inventors apply to two IIA incentive programs to support research and development of novel ideas within the hospital/community scenario:

NOFAR INCENTIVE PROGRAM

The NOFAR incentive program provides support for applied research in academia, thus potentially increasing its economic contribution to the economy. This incentive program focuses on technologically feasible ideas, which are not mature enough for the support of the MAGNETON incentive program, but require financing in the initial applied research stage at universities in order to match them with the appropriate industrial sector.

The NOFAR incentive program is limited to the fields of biotechnology and nanotechnology only, for a period of one year. To bridge the gap between academic knowledge and industry needs. All the research activities carried out as part of this incentive program are in academic institutions, accompanied by the support of an industrial company that sees business potential in the achievements of the project. The main goal is to reach significant milestones by the end of the project, which will enable the industrial company to sign a technology commercialization agreement with the research institution. The research activities in the incentive program will receive professional support by an industrial company or a relevant business entity (such as a venture capital fund).

What do you get?

• The research institution supported by the NOFAR incentive program is entitled to a grant of up to 90% of the approved budget with a maximum scope of NIS 550,000 for a period of 12 months, with an option to extend the support up to 15 months.
• The supporting company serves as partner in professional guidance and in setting of research goals, as well as participates in the funding of 10% of the project cost.
  At the end of the research, the supporting company receives the first right to negotiate a commercialization agreement with the research institution.
• NOFAR research conducted in collaboration with two different institutions is eligible for funding of up to NIS 660,000.
• The grant recipients are exempt from repayment of royalties.
• The incentive program offers two fixed annual deadlines: November 30 and May 31.

KAMIN INCENTIVE PROGRAM

The KAMIN incentive program serves as a bridge between basic and applied research and is focused on the stage of transformation and realization of basic research achievements into technologies with commercial application. To encourage applied research in academia that can attract the investment interests of business entities willing to cooperate with the research institution towards a commercialization agreement.

Research groups from Israeli universities, colleges, research institutes and medical centers that seek to conduct applied research, building upon the basic research. The research must be innovative and original in terms of industrial application; its results should be applicable to industries in Israel and potentially have high added value for the entire economy.

What do you get?

• Conditional grant of 85%-90% of the approved budget, up to a maximum amount of NIS 400,000.
• The support is provided for a period of one or two years, with the possibility to extend this period in exceptional cases with a reduced grant of 66% of the approved budget.
• The grant recipients are exempt from repayment of royalties.